JP2021528479A - ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途 - Google Patents

ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途 Download PDF

Info

Publication number
JP2021528479A
JP2021528479A JP2021500230A JP2021500230A JP2021528479A JP 2021528479 A JP2021528479 A JP 2021528479A JP 2021500230 A JP2021500230 A JP 2021500230A JP 2021500230 A JP2021500230 A JP 2021500230A JP 2021528479 A JP2021528479 A JP 2021528479A
Authority
JP
Japan
Prior art keywords
alkyl
compound
pharmaceutically acceptable
diseases
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021500230A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020007698A5 (https=
JP2021528479A5 (https=
Inventor
イェンス・セー・ヘイラン・ラーセン
モーエンス・ラーセン
アンドレアス・リッツェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of JP2021528479A publication Critical patent/JP2021528479A/ja
Publication of JPWO2020007698A5 publication Critical patent/JPWO2020007698A5/ja
Publication of JP2021528479A5 publication Critical patent/JP2021528479A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021500230A 2018-07-06 2019-06-27 ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途 Ceased JP2021528479A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18182186.9 2018-07-06
EP18182186 2018-07-06
PCT/EP2019/067127 WO2020007698A1 (en) 2018-07-06 2019-06-27 Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (3)

Publication Number Publication Date
JP2021528479A true JP2021528479A (ja) 2021-10-21
JPWO2020007698A5 JPWO2020007698A5 (https=) 2022-06-22
JP2021528479A5 JP2021528479A5 (https=) 2022-06-22

Family

ID=62874761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500230A Ceased JP2021528479A (ja) 2018-07-06 2019-06-27 ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途

Country Status (5)

Country Link
US (1) US20210269447A1 (https=)
EP (1) EP3818060B1 (https=)
JP (1) JP2021528479A (https=)
CN (1) CN112384514A (https=)
WO (1) WO2020007698A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022002210A1 (zh) * 2020-07-02 2022-01-06 南京明德新药研发有限公司 嘧啶并吡咯基类氘代化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526989A (ja) * 2005-01-13 2008-07-24 シグナル ファーマシューティカルズ，エルエルシー ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法
JP2011046700A (ja) * 2009-07-31 2011-03-10 Japan Tobacco Inc 含窒素スピロ環化合物及びその医薬用途
WO2013007768A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
JP2014515362A (ja) * 2011-05-25 2014-06-30 アルミラル・ソシエダッド・アノニマ 骨髄増殖性疾患、移植拒絶、免疫介在性疾患および炎症性疾患の処置のための医薬の製造に有用な、ピリジン−２（１ｈ）−オン誘導体
WO2018130563A1 (en) * 2017-01-11 2018-07-19 Leo Pharma A/S Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
CN104936959B (zh) * 2013-03-08 2018-09-18 中国人民解放军军事医学科学院放射与辐射医学研究所 2,6,9-三取代嘌呤衍生物及其制备方法与应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526989A (ja) * 2005-01-13 2008-07-24 シグナル ファーマシューティカルズ，エルエルシー ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法
JP2011046700A (ja) * 2009-07-31 2011-03-10 Japan Tobacco Inc 含窒素スピロ環化合物及びその医薬用途
JP2014515362A (ja) * 2011-05-25 2014-06-30 アルミラル・ソシエダッド・アノニマ 骨髄増殖性疾患、移植拒絶、免疫介在性疾患および炎症性疾患の処置のための医薬の製造に有用な、ピリジン−２（１ｈ）−オン誘導体
WO2013007768A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2018130563A1 (en) * 2017-01-11 2018-07-19 Leo Pharma A/S Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Also Published As

Publication number Publication date
EP3818060B1 (en) 2023-02-22
US20210269447A1 (en) 2021-09-02
WO2020007698A1 (en) 2020-01-09
EP3818060A1 (en) 2021-05-12
CN112384514A (zh) 2021-02-19

Similar Documents

Publication Publication Date Title
AU2024204891A1 (en) Jak1 pathway inhibitors for the treatment of cytokine-related disorders
JP7009504B2 (ja) ヤヌスキナーゼ阻害剤としての新規アミノイミダゾピリジン誘導体及びそれらの医薬としての使用
KR102598246B1 (ko) Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도
JP7101685B2 (ja) 新規ｊａｋキナーゼ阻害剤としての二環式アミン
WO2002072101A1 (en) A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
EP3576743B1 (en) 5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2 5]octane-8-carboxylic acid derivatives as jak kinase inhibitors
EP3818060B1 (en) Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
JP2002513382A (ja) アゾロトリアジン類およびアゾロピリミジン類
RU2772463C1 (ru) Новые производные аминоимидазопиримидина в качестве ингибиторов janus-киназ и их фармацевтическое применение
BR112019014191B1 (pt) Composto e composição farmacêutica
HK40013317A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
JP2021526144A (ja) Ｊａｋ３選択的阻害剤
HK40013317B (zh) 作为janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途
HK40004455A (en) Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof
HK40004455B (en) Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220613

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230912

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240130